肿瘤特异性启动子及其用途
By constructing a conditionally replicative adenovirus vector containing a tumor-specific promoter, the problem of low replication efficiency of oncolytic viruses in golden hamster tumor models was solved, achieving equivalent replication in human tumor cells and golden hamster tumor cells, thus improving the accuracy of preclinical evaluation of oncolytic virus therapy.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- BEIJING INMEI FUTURE BIOMEDICAL TECHNOLOGY CO LTD
- Filing Date
- 2026-01-11
- Publication Date
- 2026-07-17
AI Technical Summary
Existing oncolytic virus vectors are difficult to replicate effectively in golden hamster tumor models, leading to a mismatch between preclinical and clinical trial results. There is a lack of oncolytic virus platforms that can replicate equivalently in human tumor cells and golden hamster tumor cells.
By screening and optimizing tumor-specific promoters, a conditionally replicative adenovirus vector was constructed, enabling it to replicate equivalently in human tumor cells and golden hamster tumor cells. By using overlapping sequences to connect the promoter and target gene fragments, viral particles containing tumor-specific promoters were prepared.
It provides a more realistic and accurate assessment of the in vivo distribution, replication kinetics, efficacy, and potential toxicity of oncolytic viruses in a fully immune-integrated golden hamster tumor-bearing model, bridging preclinical studies and clinical trials and advancing the development of oncolytic virus drugs.
Smart Images
Figure CN121780535B_ABST
Abstract
Citation Information
Patent Citations
Construction method and application of PE38KDEL gene expression plasmid mediated by tumor specific promoter
CN109207488A
Coordinating gene expression using RNA destabilizing elements
CN111989108A